TP53 mutations in MCL: more therapy is not better

Jonathon B Cohen¹

Affiliations

PMID: 29074593
DOI: 10.1182/blood-2017-08-803551

Free article

Comment

TP53 mutations in MCL: more therapy is not better

Jonathon B Cohen. Blood. 2017.

Free article

. 2017 Oct 26;130(17):1876-1877.

doi: 10.1182/blood-2017-08-803551.

Author

Jonathon B Cohen¹

Affiliation

¹ EMORY UNIVERSITY.

PMID: 29074593
DOI: 10.1182/blood-2017-08-803551

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Comment on

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Räty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Grønbæk K. Eskelund CW, et al. Blood. 2017 Oct 26;130(17):1903-1910. doi: 10.1182/blood-2017-04-779736. Epub 2017 Aug 17. Blood. 2017. PMID: 28819011

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

TP53 mutations in MCL: more therapy is not better

Affiliation

TP53 mutations in MCL: more therapy is not better

Author

Affiliation

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous